Interest in genomic SNP testing for prostate cancer risk: a pilot survey

Hereditary Cancer in Clinical Practice

Veda N Giri¹  Laura M Gross¹  David YT Chen²  Karen J Ruth²  Michael J Hall² 

[1] Division of Population Science, Department of Medical Oncology, Thomas Jefferson University, Philadelphia, PA, USA;Fox Chase Cancer Center, Philadelphia, PA, USA

关键词: Single-nucleotide polymorphism;    Risk assessment;    Prostate cancer;    Health literacy;    Genomic testing;   

Others  :  1170915
DOI  :  10.1186/s13053-015-0032-3

 received in 2014-06-09, accepted in 2015-03-18,  发布年份 2015

【 摘 要 】

Background

Advancements in genomic testing have led to the identification of single nucleotide polymorphisms (SNPs) associated with prostate cancer. The clinical utility of SNP tests to evaluate prostate cancer risk is unclear. Studies have not examined predictors of interest in novel genomic SNP tests for prostate cancer risk in a diverse population.

Methods

Consecutive participants in the Fox Chase Prostate Cancer Risk Assessment Program (PRAP) (n = 40) and unselected men from surgical urology clinics (n = 40) completed a one-time survey. Items examined interest in genomic SNP testing for prostate cancer risk, knowledge, impact of unsolicited findings, and psychosocial factors including health literacy.

Results

Knowledge of genomic SNP tests was low in both groups, but interest was higher among PRAP men (p < 0.001). The prospect of receiving unsolicited results about ancestral genomic markers increased interest in testing in both groups. Multivariable modeling identified several predictors of higher interest in a genomic SNP test including higher perceived risk (p = 0.025), indicating zero reasons for not wanting testing (vs ≥1 reason) (p = 0.013), and higher health literacy (p = 0.016).

Conclusions

Knowledge of genomic SNP testing was low in this sample, but higher among high-risk men. High-risk status may increase interest in novel genomic tests, while low literacy may lessen interest.

【 授权许可】

   
2015 Hall et al.; licensee BioMed Central.

【 参考文献 】

• [1]Cancer Facts & Figures. In: Book Cancer Facts & Figures. American Cancer Society; 2013.
• [2]Bigler SA, Pound CR, Zhou X: A retrospective study on pathologic features and racial disparities in prostate cancer. Prostate Cancer 2011, 2011:239460.
• [3]Powell IJ, Bock CH, Ruterbusch JJ, Sakr W: Evidence supports a faster growth rate and/or earlier transformation to clinically significant prostate cancer in black than in white American men, and influences racial progression and mortality disparity. J Urol 2010, 183:1792-6.
• [4]Zeegers MP, Jellema A, Ostrer H: Empiric risk of prostate carcinoma for relatives of patients with prostate carcinoma: a meta-analysis. Cancer 2003, 97:1894-903.
• [5]Kicinski M, Vangronsveld J, Nawrot TS: An epidemiological reappraisal of the familial aggregation of prostate cancer: a meta-analysis. PLoS One 2011, 6:e27130.
• [6]Hemminki K, Sundquist J, Brandt A: Familial mortality and familial incidence in cancer. J Clin Oncol 2011, 29:712-8.
• [7]Lange EM, Salinas CA, Zuhlke KA, Ray AM, Wang Y, Lu Y, et al.: Early onset prostate cancer has a significant genetic component. Prostate 2012, 72:147-56.
• [8]NIH PDQ Cancer Information Summaries. In: Book NIH PDQ Cancer Information Summaries, 2013.
• [9]Liede A, Karlan BY, Narod SA: Cancer risks for male carriers of germline mutations in BRCA1 or BRCA2: a review of the literature. J Clin Oncol 2004, 22:735-42.
• [10]Ewing CM, Ray AM, Lange EM, Zuhlke KA, Robbins CM, Tembe WD, et al.: Germline mutations in HOXB13 and prostate-cancer risk. N Engl J Med 2012, 366:141-9.
• [11]Lindstrom S, Schumacher FR, Cox D, Travis RC, Albanes D, Allen NE, et al.: Common genetic variants in prostate cancer risk prediction–results from the NCI Breast and Prostate Cancer Cohort Consortium (BPC3). Cancer Epidemiol Biomarkers Prev 2012, 21:437-44.
• [12]Nassir R, Kosoy R, Tian C, White PA, Butler LM, Silva G, et al.: An ancestry informative marker set for determining continental origin: validation and extension using human genome diversity panels. BMC Genet 2009, 10:39. BioMed Central Full Text
• [13]Tian C, Hinds DA, Shigeta R, Kittles R, Ballinger DG, Seldin MF: A genomewide single-nucleotide-polymorphism panel with high ancestry information for African American admixture mapping. Am J Hum Genet 2006, 79:640-9.
• [14]Ricks-Santi LJ, Apprey V, Mason T, Wilson B, Abbas M, Hernandez W, et al.: Identification of genetic risk associated with prostate cancer using ancestry informative markers. Prostate Cancer Prostatic Dis 2012, 15:359-64.
• [15]Giri VN, Egleston B, Ruth K, Uzzo RG, Chen DY, Buyyounouski M, et al.: Race, genetic West African ancestry, and prostate cancer prediction by prostate-specific antigen in prospectively screened high-risk men. Cancer Prev Res (Phila) 2009, 2:244-50.
• [16]Meisfelt S, Jones S, Cohn W, Lippert M, Haden K, Turner BL, et al.: Men’s attitudes regarding testing for hereditary prostate cancer. Urology 2000, 55:46-50.
• [17]Lanie AD, Jayaratne TE, Sheldon JP, Kardia SL, Anderson ES, Feldenbaum M, et al.: Exploring the public understanding of basic genetic concepts. J Gen Counsel 2004, 13:305-20.
• [18]Donovan KA, Tucker DC: Knowledge about genetic risk for breast cancer and perceptions of genetic testing in a sociodemographically diverse sample. J Behav Med 2000, 23:15-36.
• [19]Birmingham WC, Agarwal N, Kohlmann W, Aspinwall LG, Wang M, Bishoff J, et al.: Patient and provider attitudes toward genomic testing for prostate cancer susceptibility: a mixed method study. BMC Health Serv Res 2013, 13:279. BioMed Central Full Text
• [20]Kim SP, Knight SJ, Tomori C, Colella KM, Schoor RA, Shih L, et al.: Health literacy and shared decision making for prostate cancer patients with low socioeconomic status. Cancer Invest 2001, 19:684-91.
• [21]Forman AD, Hall MJ: Influence of race/ethnicity on genetic counseling and testing for hereditary breast and ovarian cancer. Breast J 2009, 15(Suppl 1):S56-62.
• [22]Butrick M, Roter D, Kaphingst K, Erby LH, Haywood C Jr, Beach MC, et al.: Patient reactions to personalized medicine vignettes: an experimental design. Genet Med 2011, 13:421-8.
• [23]Rahm AK, Feigelson HS, Wagner N, Le AQ, Halterman E, Cornish N, et al.: Perception of direct-to-consumer genetic testing and direct-to-consumer advertising of genetic tests among members of a large managed care organization. J Genet Couns 2012, 21:448-61.
• [24]Kessler L, Collier A, Halbert CH: Knowledge about genetics among African Americans. J Genet Couns 2007, 16:191-200.
• [25]Suther S, Kiros GE: Barriers to the use of genetic testing: a study of racial and ethnic disparities. Genet Med 2009, 11:655-62.
• [26]Akinleye I, Roberts JS, Royal CDM, Linnenbringer E, Obisesan TO, Fasaye GA, et al.: Differences between African American and white research volunteers in their attitudes, beliefs and knowledge regarding genetic testing for Alzheimer’s disease. J Genet Couns 2011, 20:650-9.
• [27]Giri VN, Beebe-Dimmer J, Buyyounouski M, Konski A, Feigenberg SJ, Uzzo RG, et al.: Prostate cancer risk assessment program: a 10-year update of cancer detection. J Urol 2007, 178:1920-4. discussion 1924
• [28]Lerman C, Lustbader E, Rimer B, Daly M, Miller S, Sands C, et al.: Effects of individualized breast cancer risk counseling: a randomized trial. J Natl Cancer Inst 1995, 87:286-92.
• [29]Chew LD, Griffin JM, Partin MR, Noorbaloochi S, Grill J, Snyder A, et al.: Validation of screening questions for limited health literacy in a large VA outpatient population. J Gen Intern Med 2008, 23:561-6.
• [30]Schwartz LM, Woloshin S, Black WC, Welch HG: The role of numeracy in understanding the benefit of screening mammography. Ann Intern Med 1997, 127:966-72.
• [31]Cormier L, Valeri A, Azzouzi R, Fournier G, Cussenot O, Berthon P, et al.: Worry and attitude of men in at-risk families for prostate cancer about genetic susceptibility and genetic testing. Prostate 2002, 51:276-85.
• [32]Diefenbach MA, Schnoll RA, Miller SM, Brower L: Genetic testing for prostate cancer. Willingness and predictors of interest. Cancer Pract 2000, 8:82-6.
• [33]Little J, Wilson B, Carter R, Walker K, Santaguida P, Tomiak E, et al. Multigene Panels in Prostate Cancer Risk Assessment. Evidence Report/Technology Assessment Number 209. In: Book Multigene Panels in Prostate Cancer Risk Assessment. Evidence Report/Technology Assessment Number 209. Agency for Healthcare Research and Quality (US); 2012.
• [34]Park JH, Gail MH, Greene MH, Chatterjee N: Potential usefulness of single nucleotide polymorphisms to identify persons at high cancer risk: an evaluation of seven common cancers. J Clin Oncol 2012, 30:2157-62.
• [35]Bloom JR, Stewart SL, Oakley-Girvans I, Banks PJ, Chang S: Family history, perceived risk, and prostate cancer screening among African American men. Cancer Epidemiol Biomarkers Prev 2006, 15:2167-73.
• [36]Shavers VL, Underwood W 3rd, Moser RP: Race/ethnicity, risk perception, and receipt of prostate-specific antigen testing. J Natl Med Assoc 2009, 101:698-704.
• [37]Croyle RT, Lerman C: Interest in genetic testing for colon cancer susceptibility: cognitive and emotional correlates. Prev Med 1993, 22:284-92.
• [38]Graham ID, Logan DM, Hughes-Benzie R, Evans WK, Perras H, McAuley LM, et al.: How interested is the public in genetic testing for colon cancer susceptibility? Report of a cross-sectional population survey. Cancer Prev Control 1998, 2:167-72.
• [39]Petersen GM, Larkin E, Codori AM, Wang CY, Booker SV, Bacon J, et al.: Attitudes toward colon cancer gene testing: survey of relatives of colon cancer patients. Cancer Epidemiol Biomarkers Prev 1999, 8:337-44.
• [40]Vermeulen E, Henneman L, van El CG, Cornel MC: Public attitudes towards preventive genomics and personal interest in genetic testing to prevent disease: a survey study. Eur J Public Health 2014, 24:768-75.
• [41]Sanderson SC, Wardle J, Jarvis MJ, Humphries SE: Public interest in genetic testing for susceptibility to heart disease and cancer: a population-based survey in the UK. Prev Med 2004, 39:458-64.
• [42]Graves KD, Peshkin BN, Luta G, Tuong W, Schwartz MD: Interest in genetic testing for modest changes in breast cancer risk: implications for SNP testing. Public Health Genomics 2011, 14:178-89.
• [43]Bellcross CA, Page PZ, Meaney-Delman D: Direct-to-consumer personal genome testing and cancer risk prediction. Cancer J 2012, 18:293-302.
• [44]Peterson NB: The influence of health literacy on colorectal cancer screening knowledge, beliefs and behavior. J Natl Med Assoc 2007, 99:1105-12.
• [45]Lea DH, Kaphingst KA, Bowen D, Lipkus I, Hadley DW: Communicating Genetic and Genomic Information: Health Literacy and Numeracy Considerations. Public Health Genomics 2010, 14:279-289.
• [46]Burke W, Antommaria AH, Bennett R, Botkin J, Clayton EW, Henderson GE, et al.: Recommendations for returning genomic incidental findings? We need to talk! Genet Med 2013, 15:854-9.
• [47]Diaz VA, Mainous AG 3rd, Gavin JK, Wilson D: Racial differences in attitudes toward personalized medicine. Public Health Genomics 2014, 17:1-6.
• [48]Haga SB, O’Daniel JM, Tindall GM, Lipkus IR, Agans R: Public attitudes toward ancillary information revealed by pharmacogenetic testing under limited information conditions. Genet Med 2011, 13:723-8.
• [49]Bennette CS, Trinidad SB, Fullerton SM, Patrick D, Amendola L, Burke W, et al. Return of incidental findings in genomic medicine: measuring what patients value-development of an instrument to measure preferences for information from next-generation testing (IMPRINT). Genet Med. 2013; [Epub ahead of print].
• [50]Green RC, Berg JS, Grody WW, Kalia SS, Korf BR, Martin CL, et al.: ACMG recommendations for reporting of incidental findings in clinical exome and genome sequencing. Genet Med 2013, 15:565-74.